We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The companies had inked a deal in 2015 for commercialization of the drug, involving joint development and commercialisation of pioneering treatments in the field of Alzheimer’s disease and migraine